Intech Investment Management LLC Has $1.44 Million Stake in Protagonist Therapeutics, Inc. $PTGX

Intech Investment Management LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 36.3% during the 3rd quarter, Holdings Channel reports. The fund owned 21,643 shares of the company’s stock after selling 12,310 shares during the quarter. Intech Investment Management LLC’s holdings in Protagonist Therapeutics were worth $1,438,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PTGX. Salomon & Ludwin LLC acquired a new stake in Protagonist Therapeutics during the 3rd quarter valued at $29,000. EverSource Wealth Advisors LLC boosted its stake in Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the third quarter worth $62,000. Osaic Holdings Inc. increased its stake in shares of Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after buying an additional 525 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Protagonist Therapeutics by 11.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after buying an additional 146 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.

Insider Transactions at Protagonist Therapeutics

In other news, Director Lewis T. Williams sold 18,000 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total value of $1,483,560.00. Following the transaction, the director owned 7,825 shares of the company’s stock, valued at $644,936.50. This represents a 69.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the transaction, the chief financial officer owned 60,320 shares in the company, valued at $5,014,401.60. This represents a 43.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 203,167 shares of company stock valued at $16,889,199. 4.90% of the stock is currently owned by company insiders.

Protagonist Therapeutics Stock Up 0.7%

Shares of PTGX opened at $92.09 on Friday. Protagonist Therapeutics, Inc. has a 12-month low of $37.94 and a 12-month high of $96.54. The firm has a market capitalization of $5.88 billion, a PE ratio of -44.92 and a beta of 2.23. The stock’s fifty day simple moving average is $84.70 and its 200-day simple moving average is $78.15.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The firm had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. Analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

PTGX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Barclays raised their price objective on shares of Protagonist Therapeutics from $108.00 to $113.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. The Goldman Sachs Group boosted their target price on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the stock a “neutral” rating in a research note on Tuesday. Weiss Ratings lowered shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. Finally, Citizens Jmp increased their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.